ATM and neoplasm: Interestingly, the ATR inhibitor AZD6738 is in clinical trials in combination with olaparib in triple-negative breast cancer,67 suggesting that the effects of PARP inhibitors in combination with ATR inhibitors could be tested in patients with ATM-deficient tumours.